David Gonzalez de Castro

Professor

  • Room 0G.007 - H.S.B

    United Kingdom

19992020
If you made any changes in Pure these will be visible here soon.

Personal profile

Other

Short Biography

Professor David Gonzalez de Castro was appointed as Professor of Genomic Medicine in May 2016.  His research is centred around molecular biomarker analysis and developing genomic stratification tools for precision medicine with particular focus on developing biomarker strategies for immunotherapeutics and using circulating biomarkers to better classify and monitor disease.  He is involved in several translational research projects identifying diagnostic, predictive and prognostics molecular biomarkers in haematological and solid tumours.  Professor Gonzalez de Castro has been one of the principal investigators on the CRUK stratified medicines programme since 2011, working in close collaboration with clinicians and pharmaceutical and biotechnology industry.  For the last 12 years he has been the Head of the Molecular Diagnostics department at the Royal Marsden and the Institute of Cancer Research in London, where he has been leading the implementation of genomic medicine-driven clinical trials in multiple cancer types, including leukaemias, soft-tissue sarcomas, gastric, colon, lung, skin, prostate, breast and other tumours. He joins CCRCB and the NI-MPL as a Consultant Clinical Scientist, where he aims to further develop genomic stratification protocols to improve patients’ outcomes.

Fingerprint Dive into the research topics where David Gonzalez de Castro is active. These topic labels come from the works of this person. Together they form a unique fingerprint.

  • 29 Similar Profiles
Mutation Medicine & Life Sciences
Multiple Myeloma Medicine & Life Sciences
Neoplasms Medicine & Life Sciences
oxaliplatin Medicine & Life Sciences
Polymerase Chain Reaction Medicine & Life Sciences
Fluorescence In Situ Hybridization Medicine & Life Sciences
Gene Rearrangement Medicine & Life Sciences
B-Lymphocytes Medicine & Life Sciences

Network Recent external collaboration on country level. Dive into details by clicking on the dots.

Projects 2020 2020

Research Output 1999 2019

1 Citation (Scopus)

Analysis of KRAS, NRAS, BRAF, PIK3CA and TP53 mutations in a large prospective series of locally advanced rectal cancer patients

Sclafani, F., Hulkki Wilson, S., Cunningham, D., Gonzalez De Castro, D., Kalaitzaki, E., Begum, R., Wotherspoon, A., Capdevila, J., Glimelius, B., Roselló, S., Thomas, J., Tait, D., Brown, G., Oates, J. & Chau, I., 14 Jun 2019, In : International Journal of Cancer.

Research output: Contribution to journalArticle

Rectal Neoplasms
Mutation
Disease-Free Survival
Neoplasms
Neoplasm Genes
1 Citation (Scopus)
17 Downloads (Pure)

A tailored molecular profiling programme for children with cancer to identify clinically actionable genetic alterations

George, S. L., Izquierdo, E., Campbell, J., Koutroumanidou, E., Proszek, P., Jamal, S., Hughes, D., Yuan, L., Marshall, L. V., Carceller, F., Chisholm, J. C., Vaidya, S., Mandeville, H., Angelini, P., Wasti, A., Bexelius, T., Thway, K., Gatz, S. A., Clarke, M., Al-Lazikani, B. & 17 others, Barone, G., Anderson, J., Tweddle, D. A., Gonzalez, D., Walker, B. A., Barton, J., Depani, S., Eze, J., Ahmed, S. W., Moreno, L., Pearson, A., Shipley, J., Jones, C., Hargrave, D., Jacques, T. S., Hubank, M. & Chesler, L., Nov 2019, In : European journal of cancer (Oxford, England : 1990). 121, p. 224-235 12 p.

Research output: Contribution to journalArticle

Open Access
File
Neoplasms
DNA
Paraffin
Formaldehyde
Pediatrics

Inactivating NF1 mutations are enriched in advanced breast cancer and contribute to endocrine therapy resistance

Pearson, A., Proszek, P. Z., Pascual, J., Fribbens, C., Shamsher, M. K., Kingston, B., O'Leary, B., Herrera-Abreu, M. T., Cutts, R. J., Garcia-Murillas, I., Bye, H., Walker, B. A., Gonzalez De Castro, D., Yuan, L., Jamal, S., Hubank, M., López-Knowles, E., Schuster, E. F., Dowsett, M., Osin, P. & 6 others, Nerurkar, A., Parton, M., Okines, A. F., Johnston, S. R. D., Ring, A. & Turner, N. C., 07 Oct 2019, In : Clinical Cancer Research.

Research output: Contribution to journalArticle

Breast Neoplasms
Mutation
Therapeutics
Neoplasms
Disease Progression
1 Citation (Scopus)
62 Downloads (Pure)

Investigating the potential clinical benefit of Selumetinib in resensitising advanced iodine refractory differentiated thyroid cancer to radioiodine therapy (SEL-I-METRY): protocol for a multicentre UK single arm phase II trial

Hall, A., Buckley, H. L., Flanagan, L., Gonzalez de Castro, D., Farnell, K., Moss, L., Gregory, R., Newbold, K., Du, Y., Flux, G. & Wadsley, J., 14 Jun 2019, In : BMC Cancer. 19, 10 p., 582.

Research output: Contribution to journalArticle

Open Access
File
Thyroid Neoplasms
Iodine
Therapeutics
Multicenter Studies
Disease-Free Survival
46 Downloads (Pure)
Open Access
File
cancer
neoplasms
tumor
Neoplasms
trajectory